March 22, 2021
Video
Newer therapies being explored to address treatment gaps in acute graft-versus-host disease (GVHD), and advice to community oncologists/hematologists who manage cases of GVHD and/or care for patients who receive allotransplants.
March 22, 2021
Video
The rationale for treating steroid-refractory acute graft-versus-host disease with ruxolitinib, a JAK inhibitor, and recommendations for monitoring and managing treatment-related adverse events.
March 22, 2021
Video
Dr Michael Bishop, of the David and Etta Jonas Center for Cellular Therapy, University of Chicago, describes the rationale for the design of the phase 3 REACH2 trial in steroid-refractory acute graft-versus-host disease and provides perspective on important takeaways from data presented.
March 22, 2021
Video
Considerations for assessing response to steroid therapy as initial therapy for acute graft-versus-host disease and factors that impact next-line therapy, when necessary.